FOXP3 and neoplasm: Previously, Liu et al. reported a significant decrease in peritumoral FOXP3+ TILs in TNBC and HER2+ tumors post-PST, but not in hormone receptor-positive tumors; furthermore, FOXP3+ TILs within tumor bed remained stable [23].